Abizer Gaslightwala insider trades: Akari Therapeutics (AKTX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Abizer reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 25, 2025 | AKTX | ↑ Buy | 21,000 | $0.93 | $20K | Direct | Aug 29, 2025 (4d) |
| Jun 24, 2025 | AKTX | ↑ Buy | 6,146 | $1.16 | $7K | Direct | Jun 25, 2025 (1d) |
| Jun 20, 2025 | AKTX | ↑ Buy | 10,000 | $1.20 | $12K | Direct | Jun 24, 2025 (4d) |
| Jun 17, 2025 | AKTX | ↑ Buy | 15,000 | $1.20 | $18K | Direct | Jun 20, 2025 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Abizer Gaslightwala's insider trades
Abizer Gaslightwala is CEO at Akari Therapeutics (AKTX). Since Jun 17, 2025, Abizer has reported 4 open-market purchases worth $57K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), option exercises (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.